Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer.

D. F. Hayes, T. M. Walker, B. Singh, E. S. Vitetta, J. W. Uhr, S. Gross, C. Rao, G. V. Doyle, L. W. Terstappen

Research output: Contribution to journalArticle

137 Citations (Scopus)

Abstract

Nineteen breast cancer patients with measurable metastatic disease who were starting an initial or new line of therapy were evaluated for circulating epithelial cells (CECs) a minimum of 4 times over the course of treatment. In 7 of the 10 CEC+ patients, HER-2 expression was detected on the CECs. CECs expressing HER-2 varied among patients and in serial samples from the same patient including a shift from HER-2- to HER-2+ CECs. These results demonstrate that it is possible to quantify receptors essential for rationally designed therapy using CECs and that reliance on the immunophenotype of the primary tumor can be misleading.

Original languageEnglish (US)
Pages (from-to)1111-1117
Number of pages7
JournalInternational Journal of Oncology
Volume21
Issue number5
StatePublished - Nov 2002

Fingerprint

Epithelial Cells
Breast Neoplasms
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hayes, D. F., Walker, T. M., Singh, B., Vitetta, E. S., Uhr, J. W., Gross, S., ... Terstappen, L. W. (2002). Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. International Journal of Oncology, 21(5), 1111-1117.

Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. / Hayes, D. F.; Walker, T. M.; Singh, B.; Vitetta, E. S.; Uhr, J. W.; Gross, S.; Rao, C.; Doyle, G. V.; Terstappen, L. W.

In: International Journal of Oncology, Vol. 21, No. 5, 11.2002, p. 1111-1117.

Research output: Contribution to journalArticle

Hayes, DF, Walker, TM, Singh, B, Vitetta, ES, Uhr, JW, Gross, S, Rao, C, Doyle, GV & Terstappen, LW 2002, 'Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer.', International Journal of Oncology, vol. 21, no. 5, pp. 1111-1117.
Hayes, D. F. ; Walker, T. M. ; Singh, B. ; Vitetta, E. S. ; Uhr, J. W. ; Gross, S. ; Rao, C. ; Doyle, G. V. ; Terstappen, L. W. / Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. In: International Journal of Oncology. 2002 ; Vol. 21, No. 5. pp. 1111-1117.
@article{9aab58e5d9fd462a962f06b8ef87df0d,
title = "Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer.",
abstract = "Nineteen breast cancer patients with measurable metastatic disease who were starting an initial or new line of therapy were evaluated for circulating epithelial cells (CECs) a minimum of 4 times over the course of treatment. In 7 of the 10 CEC+ patients, HER-2 expression was detected on the CECs. CECs expressing HER-2 varied among patients and in serial samples from the same patient including a shift from HER-2- to HER-2+ CECs. These results demonstrate that it is possible to quantify receptors essential for rationally designed therapy using CECs and that reliance on the immunophenotype of the primary tumor can be misleading.",
author = "Hayes, {D. F.} and Walker, {T. M.} and B. Singh and Vitetta, {E. S.} and Uhr, {J. W.} and S. Gross and C. Rao and Doyle, {G. V.} and Terstappen, {L. W.}",
year = "2002",
month = "11",
language = "English (US)",
volume = "21",
pages = "1111--1117",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer.

AU - Hayes, D. F.

AU - Walker, T. M.

AU - Singh, B.

AU - Vitetta, E. S.

AU - Uhr, J. W.

AU - Gross, S.

AU - Rao, C.

AU - Doyle, G. V.

AU - Terstappen, L. W.

PY - 2002/11

Y1 - 2002/11

N2 - Nineteen breast cancer patients with measurable metastatic disease who were starting an initial or new line of therapy were evaluated for circulating epithelial cells (CECs) a minimum of 4 times over the course of treatment. In 7 of the 10 CEC+ patients, HER-2 expression was detected on the CECs. CECs expressing HER-2 varied among patients and in serial samples from the same patient including a shift from HER-2- to HER-2+ CECs. These results demonstrate that it is possible to quantify receptors essential for rationally designed therapy using CECs and that reliance on the immunophenotype of the primary tumor can be misleading.

AB - Nineteen breast cancer patients with measurable metastatic disease who were starting an initial or new line of therapy were evaluated for circulating epithelial cells (CECs) a minimum of 4 times over the course of treatment. In 7 of the 10 CEC+ patients, HER-2 expression was detected on the CECs. CECs expressing HER-2 varied among patients and in serial samples from the same patient including a shift from HER-2- to HER-2+ CECs. These results demonstrate that it is possible to quantify receptors essential for rationally designed therapy using CECs and that reliance on the immunophenotype of the primary tumor can be misleading.

UR - http://www.scopus.com/inward/record.url?scp=0036834995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036834995&partnerID=8YFLogxK

M3 - Article

C2 - 12370762

AN - SCOPUS:0036834995

VL - 21

SP - 1111

EP - 1117

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 5

ER -